BioChange Overview
BioChange specializes in tissue regeneration technology and is the developer of CellFoam, an injectable scaffold that stimulates tissue repair and remodeling at the site of injection. Based on natural biomaterials designed for implantation using a minimally invasive procedure, the scaffold mimics the healthy extra-cellular matrix and triggers the body to repair itself.
Cumulative Funding Raised Over Time ($)
$3.0MJul 2023
$3.0MOct 2021
Latest News
Israeli foam to reverse receding gums soon set for human use, after success on dogs
growth-positive
Dental implant holds promise for gum repair, regeneration - ISRAEL21c
Israeli startup BioChange has developed a tissue regeneration technology, ReGum, that has been shown to be effective in healing gum disease in dogs. The product is now commercially available for veterinary use and is reportedly the only product of its kind. A formulation for humans is expected within a few years. The products success was reported in the journal Frontiers in Veterinary Science. The company is now selling products in the veterinary and research markets and is committed to beginning its first clinical study in aesthetic dermatology in 2023.
CustomersExpand
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | $3.05M |
| Last funding | $3M |
| Stage | Seed |
| Rounds | 3 |
| Investors | 2 |
Team Members
5
Employees: 11-50
Web & Social Links
| Website | biochange.life/?v=4605f628f91d |
Locations
HaYetsira St 13, Yokne'am Illit, Israel
Photos & Videos
2 item(s)
BioChange Business
Business models
B2B
Product stage
Released
Employees
11-50
Sector
Health Tech & Life SciencesPharma & Medical BiotechnologyBiomaterials & Tissue EngineeringTarget Customer
Healthcare & Life SciencesLife SciencesCosmeticsHealthcareProvidersConsumersRecreational & LifestylePet OwnersCore Technology
BiologicalsCellsTags (14)
biodegradabledogspet-ownerstreatmentsbiotechnologytissue-regenerationdoctorsmedical-devicesminimally-invasiveregenerative-medicinemedical-technologiesveterinarydermatologyurologyGeographic Markets
GlobalBioChange Financials
$3.05M
Total funding
Undisclosed
Capital raised
$3M
Last funding
Seed
Funding stage
3
Total rounds
2
Investors
Cumulative Funding Raised Over Time ($)
$3.0MJul 2023
$3.0MOct 2021
Private Equity Funding
Undisclosed Round
Jul 2023
$3M
quadraScope (Lead)
Equity crowdfunding
Oct 2021
Undisclosed
ExitValley
Non-Equity Funding
GrantEvent
Aug 2017
$50K
EU Horizon 2020
BioChange Lifecycle
Cumulative Funding Raised Over Time
$3.0MJul 2023
$3.0MOct 2021
All Events
Undisclosed Round
Jul 2023
$3M
quadraScope (Lead)
Equity crowdfunding
Oct 2021
Undisclosed
ExitValley
GrantEvent
Aug 2017
$50K
EU Horizon 2020
BioChange News
2 articlesIsraeli foam to reverse receding gums soon set for human use, after success on dogs
growth-positive
Dental implant holds promise for gum repair, regeneration - ISRAEL21c
Israeli startup BioChange has developed a tissue regeneration technology, ReGum, that has been shown to be effective in healing gum disease in dogs. The product is now commercially available for veterinary use and is reportedly the only product of its kind. A formulation for humans is expected within a few years. The products success was reported in the journal Frontiers in Veterinary Science. The company is now selling products in the veterinary and research markets and is committed to beginning its first clinical study in aesthetic dermatology in 2023.
CustomersExpand
BioChange Team
Employee Info
| Employees (range) | 11-50 |
| Exact count | 17 |
| Team members | 5 |
Similar Companies
Similar companies data is computed dynamically and not stored in the entity profile. This section requires implementing a similarity query (e.g. by classification overlap, sector, district).
This entity has 13 classification IDs that could be used for matching.
BioChange Internal
Recent Updates
No update log entries.
Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.
Admin Info
| Confidence | 100/100 |
| Missing | markets |
| BI Verification | Maor Perlov |
| Registrar ID | 514903749 |
| Crunchbase | biochange-ltd |
| Phone | 0508449619 |
| Creator | Yotam Maman |
| Creator email | yotamm1988@gmail.com |
| Last updater | Yanina Wainscheinker |
| Updater email | yanina.wainscheinker@sncentral.org |
| Last update | 2023-10-16T00:00:00.000Z |
| Created | 2020-07-13T00:00:00.000Z |
| Claimed | Yes |